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###### Baseline characteristics of the 91 Czech patients with biopsy-proven IgA nephropathy.

(DOCX)

###### 

Click here for additional data file.

###### Baseline characteristics of the three groups of the 91 Czech patients with biopsy-proven IgA nephropathy (non-progressors, progressors, patients with ESRD).

(DOCX)

###### 

Click here for additional data file.

###### Analysis of a combined group of IgAN non-progressors and progressors vs. IgAN patients who reached ESRD.

(DOCX)

###### 

Click here for additional data file.

###### Median test (Mood test) comparing IgAN patients with end-stage renal disease reached during the follow-up *vs*. IgAN patients without ESRD for selected variables.

(DOCX)

###### 

Click here for additional data file.

###### Assessment of two groups (non-progressors \[n = 70\] and progressors \[n = 7\]) for the influence of E from the Oxford classification (MEST); other parameters (M, S, T) did not reach significance).

(DOCX)

###### 

Click here for additional data file.

###### Influence of Oxford classification MEST composite score in assessment of two groups (non-progressors \[n = 70\] and progressors \[n = 7\]).

(DOCX)

###### 

Click here for additional data file.

###### Mean values of selected laboratory parameters in a subset of patients treated with corticosteroids in group 1 with eGFR ≥60 mL/min/1.73 m2 (n = 16) and group 2 with eGFR \<60 mL/min/1.73 m2 (n = 24).

(DOCX)

###### 

Click here for additional data file.

###### Discriminant analysis for three groups of IgAN patients (non-progressors in green, progressors in orange, ESRD in blue) and all parameters (eGFR, using MDRD formula (mL/min/1.73 m2); serum IgA (mg/mL); serum Gd-IgA1 (U/1 ∝g IgA; without neuraminidase); serum Gd-IgA1 (U/mL; without neuraminidase); serum Gd-IgA1 (U/1 ∝g IgA; with neuraminidase); serum Gd-IgA1 (U/mL; with neuraminidase).

(DOCX)

###### 

Click here for additional data file.

###### Box-and-whiskers plots for progressors and non-progressors (group 1) *vs*. IgAN patients who reached ESRD during follow up (group 2) for selected parameters.

(DOCX)

###### 

Click here for additional data file.

###### Receiver operating characteristic (ROC) curves for non-progressors *vs*. progressors.

a- ROC curve for non-progressors *vs*. progressors using eGFR (MDRD, mL/min/1.73 m^2^), Gd-IgA1 biomarkers, and Oxford classification (individual parameters of Oxford MEST classification). Area under the curve, AUC = 0.936. b- Receiver operating characteristic (ROC) curve for non-progressors *vs*. progressors using eGFR (MDRD, mL/min/1.73 m^2^) and Oxford classification (individual parameters of Oxford MEST classification). Area under the curve, AUC = 0.836.

(DOCX)

###### 

Click here for additional data file.

###### Receiver operator curve within two groups (eGFR, serum levels of IgG autoantibody specific for Gd-IgA1).

Area under the curve = 1.00. Accuracy of the discrimination is 100%. Group 1 (n = 35), eGFR ≥60 mL/min/1.73 m^2^ at the time of renal-biopsy; group 2 (n = 42), eGFR \<60 mL/min/1.73 m^2^ at the time of renal-biopsy. Prediction equation from logistic regression (predicts probability to choose group 1): Pred(group 1) = 1 / (1 + exp(-(1517.5--1.2E-02\**AB-IgA*-24.9\**eGFR*))).

(DOCX)

###### 

Click here for additional data file.

###### Box-and-whiskers plots for selected variables within two groups.

S-creat, serum creatinine (μmol/L); eGFR (MDRD, mL/min/1.73 m2); serum IgG autoantibody specific for Gd-IgA1 (U/mL). Group 1 (n = 35), eGFR ≥60 mL/min/1.73 m2 at the time of renal biopsy; group 2 (n = 42), eGFR \<60 mL/min/1.73 m2 at the time of renal biopsy.

(DOCX)

###### 

Click here for additional data file.
